Hapten Pharmaceuticals

RXi Pharmaceuticals, Hapten Pharmaceuticals ink agreement

Friday, December 19, 2014

RXi Pharmaceuticals, a Marlborough, Mass.,-based biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, an early stage dermatology product development company based in New York, for the therapeutic use of Samcyprone.

[Read More]